Internal Medicine, Hematology · San Antonio, TX
NPI
1801860168
Since 2006
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
7979 Wurzbach Rd Ste 2222
San Antonio, TX, 78229
Phone (210) 450-1143
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
59,707 services
Medicare patients, 2024
245
Average age 73
Drug cost, 2024
$4.1M
534 prescriptions
Company payments, 2025
$2,630
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Montaser Shaheen was code J9299 (injection, nivolumab, 1 mg), 15,020 times for 18 patients. In total Montaser Shaheen billed 59,707 services in 111 codes, and Medicare paid $1.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-12-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9299 Injection, nivolumab, 1 mg | Office | 15,020 | 18 | $24.78 | $372K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,800 | 21 | $44.75 | $439K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,300 | 11 | $0.12 | $385 |
| J0897 Injection, denosumab, 1 mg | Office | 1,860 | 11 | $20.93 | $39K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 666 | 33 | $0.09 | $59.59 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 364 | 22 | $0.07 | $26.85 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 230 | 12 | $0.75 | $173 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 176 | 74 | $13.14 | $2,313 |
| 96413 Chemotherapy Administration | Office | 171 | 92 | $97.60 | $17K |
| 99215 Office E&M - Established | Office | 129 | 56 | $142.20 | $18K |
| 99214 Office E&M - Established | Office | 129 | 56 | $100.13 | $13K |
| 96375 Injection Administration | Office | 128 | 43 | $12.32 | $1,576 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 70 | 17 | $0.49 | $33.95 |
| 96367 Intravenous Infusion, Hydration | Office | 70 | 38 | $22.74 | $1,592 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 40 | 21 | $0.64 | $25.79 |
By year: 2022 $343K for 13,391 services; 2023 $1.0M for 44,886 services; 2024 $1.6M for 59,707 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 54 | 47 | $2.94 | $159 |
| 80053 Clinical Chemistry | 49 | 42 | $10.35 | $507 |
| 85025 Blood Count | 46 | 40 | $7.61 | $350 |
| 83615 Clinical Chemistry | 34 | 27 | $5.92 | $201 |
| 83540 Clinical Chemistry | 14 | 14 | $6.34 | $88.76 |
| 83550 Clinical Chemistry | 14 | 14 | $8.57 | $120 |
| 82728 Clinical Chemistry | 14 | 14 | $13.36 | $187 |
| 84443 Clinical Chemistry | 11 | 11 | $16.48 | $181 |
Medicare prescription drug claims, 2024
In 2024, the drug Montaser Shaheen prescribed most often to Medicare patients was Cabometyx (Cabozantinib S-Malate), with 99 prescriptions and refills. In total Montaser Shaheen wrote 534 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cabometyx Cabozantinib S-Malate | 99 | 101 | 20 | $2.6M |
| Amlodipine Besylate Generic | 36 | 76 | 13 | $190 |
| Methylprednisolone Generic | 30 | 30 | 17 | $252 |
| Levothyroxine Sodium Generic | 28 | 42 | 11 | $153 |
| Hydrocortisone Generic | 23 | 34 | Under 11 | $1,278 |
| Anastrozole Generic | 18 | 32 | Under 11 | $197 |
| Prednisone Generic | 17 | 17 | 11 | $101 |
| Triamcinolone Acetonide Generic | 17 | 18 | Under 11 | $87.22 |
| Bicalutamide Generic | 16 | 20 | Under 11 | $192 |
| Doxepin Hcl Generic | 16 | 16 | Under 11 | $234 |
| Xtandi Enzalutamide | 14 | 14 | Under 11 | $201K |
| Welireg Belzutifan | 12 | 12 | Under 11 | $351K |
| Synthroid Levothyroxine Sodium | 12 | 14 | Under 11 | $596 |
| Inlyta Axitinib | 12 | 12 | Under 11 | $257K |
Brand drugs: 213 claims; generic drugs: 321 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Montaser Shaheen $2,630 (- in general payments such as food, travel and fees and $2,630 for research) from 3 companies. The largest payer was Regeneron Pharmaceuticals, Inc. with $2,630.
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. REGN | 1 | $2,630 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.